ACCENDRA HEALTH INC/VA/
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.8B | $2.7B | $2.6B | $10.0B | $9.8B |
| Cost of revenue | $1.5B | $1.4B | $1.3B | $8.1B | $8.3B |
| Gross profit | — | $2.2B | $2.1B | $1.8B | $1.5B |
| Selling, general & administrative | $1.1B | $1.1B | $1.0B | $1.6B | $1.1B |
| Research and development | — | $13.0M | $13.0M | $12.0M | $12.1M |
| Operating income | $27.5M | -$217.7M | $133.2M | $142.9M | $368.5M |
| Interest expense | $107.2M | $107.6M | $116.8M | $128.9M | $48.1M |
| Pretax income | -$102.0M | -$329.9M | $15.3M | $10.9M | $276.8M |
| Income tax expense | $729,000 | $20.9M | $6.4M | -$11.5M | $55.2M |
| Net income | -$1.1B | -$362.7M | -$41.3M | $22.4M | $221.6M |
| Balance Sheet | |||||
| Cash and equivalents | $282.0M | $27.6M | $243.0M | $69.5M | $55.7M |
| Current assets | $547.9M | $2.0B | $2.1B | $2.3B | $2.3B |
| Total assets | $2.5B | $4.7B | $5.1B | $5.4B | $3.5B |
| Current liabilities | $947.1M | $1.9B | $1.9B | $1.6B | $1.3B |
| Total liabilities | $2.9B | $4.1B | $4.2B | $4.4B | $2.6B |
| Stockholders' equity | -$461.0M | $586.4M | $945.3M | $966.7M | $938.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$101.8M | $161.5M | $740.7M | $325.0M | $124.2M |
| Depreciation and amortization | $214.5M | $181.3M | $210.4M | $228.7M | $90.6M |
| Stock-based compensation | $12.9M | $16.6M | $14.4M | $21.0M | $25.0M |
| Capital expenditure | $191.0M | $170.3M | $172.4M | $158.1M | $41.0M |
| Free cash flow | -$292.7M | -$8.8M | $568.3M | $166.9M | $83.2M |
| Dividends paid | — | — | $0 | $0 | $731,000 |
| Share repurchases | $10.2M | — | — | — | — |
| Impairments | $0 | $307.1M | $0 | $0 | $0 |
Shares outstanding 76.6M · Free float 54.6%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.